UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043445
Receipt number R000049611
Scientific Title Effect of lactulose ingestion on ammonia gas emitted from human skin.
Date of disclosure of the study information 2021/02/26
Last modified on 2021/08/30 10:15:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of lactulose ingestion on ammonia gas emitted from human skin.

Acronym

Effect of lactulose ingestion on ammonia gas emitted from human skin.

Scientific Title

Effect of lactulose ingestion on ammonia gas emitted from human skin.

Scientific Title:Acronym

Effect of lactulose ingestion on ammonia gas emitted from human skin.

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the skin ammonia gas emission inhibitory effect of a single ingestion of 4 g of lactulose under protein loading conditions.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Emission flux of Ammonia gas from human skin (AUC)

Key secondary outcomes

Emission flux of Ammonia gas from human skin (Peak value), Stool forms


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking


Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Single intake of 4g lactulose

Interventions/Control_2

Single intake of placebo

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

Healthy people

Key exclusion criteria

1) Subjects with severe hepatic, renal, heart, gastrointestinal, cerebrovascular, endocrine, metabolic or infection diseases.
2) Subjects with the history of gastrointestinal resection.
3) Subjects with gastrointestinal dysfunction such as irritable bowel syndrome or inflammatory bowel disease.
4) Subjects who use medicines or supplements that may influence feces frequency; e.g. antibiotics, probiotics, laxatives, antidiarrheals, fibers.
5) Subjects with milk allergy, metal allergy, or lactose intolerance.
6) Subjects who participate another study.
7) Subjects who are judged inappropriate for the study by the investigator or the physician.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Yoshika
Middle name
Last name Sekine

Organization

Tokai University

Division name

Graduate School of Science

Zip code

259-1207

Address

4-1-1 Kitakaname, Hiratsuka-shi, Kanagawa

TEL

0463-58-1211

Email

sekine@keyaki.cc.u-tokai.ac.jp


Public contact

Name of contact person

1st name Yoshika
Middle name
Last name Sekine

Organization

Tokai University

Division name

Graduate School of Science

Zip code

259-1207

Address

4-1-1 Kitakaname, Hiratsuka-shi, Kanagawa

TEL

0463-58-1211

Homepage URL


Email

sekine@keyaki.cc.u-tokai.ac.jp


Sponsor or person

Institute

Tokai University

Institute

Department

Personal name



Funding Source

Organization

Morinaga Milk Industry Co., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

TOKAI DAIGAKU " hito wo taisho to suru kenkyu"ni kansuru rinriiinnkai

Address

4-1-1 Kitakaname, Hiratsuka-shi, Kanagawa

Tel

0463-58-1211

Email

sekine@keyaki.cc.u-tokai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 02 Month 17 Day

Date of IRB

2021 Year 02 Month 25 Day

Anticipated trial start date

2021 Year 02 Month 26 Day

Last follow-up date

2021 Year 03 Month 24 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 02 Month 26 Day

Last modified on

2021 Year 08 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049611


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name